详情页 - 聚合机构库演示平台

资源类型：

文章类型：

作者：

Ren, Chao[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] * ; Wei, Xiao-Li[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Xu, Nong[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Shen, Lin[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Dai, Guanghai[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Yuan, Xianglin[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19]

; Chen, Ye[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Yang, Shujun[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Shi, Jianhua[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Hu, Xichun[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Lin, Xiaoyan[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Zhang, Qingyuan[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Feng, Jifeng[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Ba, Yi[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Liu, Yunpeng[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Liu, Wei[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Shu, Yongqian[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Xu, Rui-hua[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Junshi, Shanghai[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ;

单位： [1]Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China [2]Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China,Dept Med Oncol, Guangzhou, Peoples R China [3]Zhejiang Univ, Affiliated Hosp 1, Dept Med Oncol, Hangzhou, Peoples R China [4]Peking Univ, Dept Gastrointestinal Oncol, Key Lab Carcinogenesis & Translat Res, Canc Hosp & Inst,Minist Educ, Beijing, Peoples R China [5]Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China [6]Huazhong Univ Sci & Technol, Tongji Hosp, Dept Oncol, Wuhan, Peoples R China [7]Sichuan Univ, West China Hosp, Chengdu, Peoples R China [8]Henan Canc Hosp, Zhengzhou, Peoples R China [9]Linyi Canc Hosp, Linyi, Shandong, Peoples R China [10]Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China [11]Fujian Med Univ, Dept Med Oncol, Union Hosp, Fuzhou, Fujian, Peoples R China [12]Harbin Med Univ, Canc Hosp, Harbin, Peoples R China [13]Jiangsu Canc Hosp, Nanjing, Peoples R China [14]Jiangsu Inst Canc Res, Nanjing, Peoples R China [15]Nanjing Med Univ, Affiliated Canc Hosp, Nanjing, Peoples R China [16]Tianjin Canc Hosp, Dept Med Oncol, Tianjin, Peoples R China [17]China Med Univ, Dept Oncol, Hosp 1, Shenyang, Peoples R China [18]First Hosp Jilin Univ, Changchun, Peoples R China [19]Jiangsu Prov Hosp, Nanjing, Peoples R China

出处：

ISSN：

基金：

语种：

被引次数：

WOS：

中科院(CAS)分区：

出版当年[2019]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

JCR分区：

出版当年[2018]版：

Q1 ONCOLOGY

最新[2024]版：

Q1 ONCOLOGY

第一作者：

第一作者单位： [1]Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China [2]Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China,Dept Med Oncol, Guangzhou, Peoples R China [3]Zhejiang Univ, Affiliated Hosp 1, Dept Med Oncol, Hangzhou, Peoples R China [4]Peking Univ, Dept Gastrointestinal Oncol, Key Lab Carcinogenesis & Translat Res, Canc Hosp & Inst,Minist Educ, Beijing, Peoples R China [5]Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China [6]Huazhong Univ Sci & Technol, Tongji Hosp, Dept Oncol, Wuhan, Peoples R China [7]Sichuan Univ, West China Hosp, Chengdu, Peoples R China [8]Henan Canc Hosp, Zhengzhou, Peoples R China [9]Linyi Canc Hosp, Linyi, Shandong, Peoples R China [10]Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China [11]Fujian Med Univ, Dept Med Oncol, Union Hosp, Fuzhou, Fujian, Peoples R China [12]Harbin Med Univ, Canc Hosp, Harbin, Peoples R China [13]Jiangsu Canc Hosp, Nanjing, Peoples R China [14]Jiangsu Inst Canc Res, Nanjing, Peoples R China [15]Nanjing Med Univ, Affiliated Canc Hosp, Nanjing, Peoples R China [16]Tianjin Canc Hosp, Dept Med Oncol, Tianjin, Peoples R China [17]China Med Univ, Dept Oncol, Hosp 1, Shenyang, Peoples R China [18]First Hosp Jilin Univ, Changchun, Peoples R China [19]Jiangsu Prov Hosp, Nanjing, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

Clinical response and biomarker analysis of a phase II basket trial of toripalimab, a PD-1 mAb in combination with standard chemotherapy as a first-line treatment for patients with solid tumors.

文献详情